ProCE Banner Activity

Expert Q&A – Asthma Management: Applying Phenotyping and Endotyping to Improve Outcomes in Uncontrolled Asthma

Text Module

During PCE's recent Pulmonary Bootcamp, attendees had the chance to ask our expert faculty a variety of questions about severe and uncontrolled asthma. Here, Ann Hefel, MS, FNP-BC, RN, instructor in the Department of Pediatric Allergy and Immunology at the University of Colorado School of Medicine, and Mark Liu, MD, associate professor of Medicine in the Division of Pulmonology and Critical Care Medicine at Johns Hopkins University, provide their responses to the questions asked during the live presentation. We hope you will find their responses relevant to your practice.

In Partnership With the Association of Pulmonary Advanced Practice Providers


Released: December 10, 2021

Expiration: December 09, 2022



Ann Hefel

Ann Hefel, FNP-BC, MS, RN

Department of Pediatrics, Allergy & Immunology
University of Colorado
Aurora, Colorado

Mark Liu

Mark Liu, MD

Associate Professor of Medicine
Division of Pulmonology and Critical Care Medicine
Johns Hopkins University
Baltimore, Maryland


This program is cosupported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson; Genentech, a member of the Roche Group; GlaxoSmithKline; Jazz Pharmaceuticals, Inc.; and Mylan Specialty L.P.

This activity is supported by educational grants from Genentech, a member of the Roche Group; and GlaxoSmithKline.


Ms Hefel has no relevant financial relationships to disclose.

Dr Liu: consulting fees: AstraZeneca; contracted research/consulting fees: GlaxoSmithKline, Gossamer Bio.

Additional Information

Program Medium

This program has been made available online.